We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-3.25%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.29B
AUM Growth
-$158M
Cap. Flow
-$42M
Cap. Flow %
-1.83%
Top 10 Hldgs %
41.8%
Holding
210
New
13
Increased
53
Reduced
56
Closed
18

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$16.6M
2
ILMN icon
Illumina
ILMN
+$12.9M
3
HUM icon
Humana
HUM
+$10.1M
4
BIIB icon
Biogen
BIIB
+$7.74M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$6.2M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$18.7M
2
ABT icon
Abbott
ABT
+$15.4M
3
ARRY
Array Biopharma Inc
ARRY
+$15M
4
TMO icon
Thermo Fisher Scientific
TMO
+$13.4M
5
LLY icon
Eli Lilly
LLY
+$10.7M

Sector Composition

Rank Sector Weight
1 Healthcare 94.94%
2 Real Estate 3.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BSX icon
26
Boston Scientific
BSX
$68.4B
$23M 1%
564,950
-67,300
-11% -$2.85M
DHR icon
27
Danaher
DHR
$138B
$22M 0.96%
171,880
-7,394
-4% -$926K
NVS icon
28
Novartis
NVS
$301B
$21.7M 0.95%
249,447
-27,600
-10% -$2.48M
HUM icon
29
Humana
HUM
$44B
$21.5M 0.94%
84,234
+36,112
+75% +$10.1M
VTRS icon
30
Viatris
VTRS
$20.7B
$20.5M 0.9%
1,038,554
+95,402
+10% +$1.87M
CI icon
31
Cigna
CI
$76.1B
$19M 0.83%
124,995
+8,239
+7% +$1.34M
NBIX icon
32
Neurocrine Biosciences
NBIX
$18.7B
$18.6M 0.81%
206,822
-256
-0.1% -$23.9K
LLY icon
33
Eli Lilly
LLY
$1.03T
$17.6M 0.77%
156,958
-96,241
-38% -$10.7M
BMRN icon
34
BioMarin Pharmaceuticals
BMRN
$11.7B
$16.6M 0.72%
245,763
– –
PRAH
35
DELISTED
PRA Health Sciences, Inc.
PRAH
$15.2M 0.66%
153,003
– –
BDX icon
36
Becton Dickinson
BDX
$45.6B
$14.8M 0.64%
59,899
– –
MCK icon
37
McKesson
MCK
$101B
$14.7M 0.64%
107,266
+11,575
+12% +$1.64M
BAX icon
38
Baxter International
BAX
$13.8B
$14.4M 0.63%
164,958
-11,740
-7% -$1M
COR icon
39
Cencora
COR
$60.7B
$14.4M 0.63%
174,338
+34,065
+24% +$2.93M
EW icon
40
Edwards Lifesciences
EW
$50B
$14.3M 0.63%
195,720
-13,587
-6% -$954K
WELL icon
41
Welltower
WELL
$170B
$13.8M 0.6%
152,322
– –
IDXX icon
42
Idexx Laboratories
IDXX
$44.1B
$13.5M 0.59%
49,776
-11,978
-19% -$3.33M
ALNY icon
43
Alnylam Pharmaceuticals
ALNY
$27.4B
$13.4M 0.58%
166,275
+4,903
+3% +$388K
BLUE
44
DELISTED
bluebird bio
BLUE
$12.9M 0.56%
10,830
+2,962
+38% +$4.52M
NVO
45
Novo Nordisk
NVO
$228B
$12.5M 0.54%
482,000
– –
AZN icon
46
AstraZeneca
AZN
$266B
$12.3M 0.54%
138,049
-29,450
-18% -$2.55M
SAGE
47
DELISTED
Sage Therapeutics
SAGE
$12.2M 0.53%
86,780
+2,635
+3% +$441K
HCA icon
48
HCA Healthcare
HCA
$85.7B
$11.8M 0.52%
98,393
+8,824
+10% +$1.14M
ONC
49
BeOne Medicines Ltd
ONC
$33.4B
$11.5M 0.5%
94,289
-600
-0.6% -$79.7K
OHI icon
50
Omega Healthcare
OHI
$15B
$11.4M 0.5%
272,766
– –
1
2
3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2019 Portfolio in Review

As of Q3 2019, Tekla Capital Management held 210 positions worth $2.29B, down 6.5% from $2.45B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Tekla Capital Management's Q3 2019 filing shows 13 new, 53 increased, 56 reduced and 18 closed positions. Its largest new stake was Insmed: 164,786 shares worth $2.91M. The largest sale was Amgen, an estimated $18.7M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 95% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q3 2019 buy was Insmed: 164,786 shares worth $2.91M.
  • Tekla Capital Management added most to Merck in Q3 2019, an estimated $16.6M increase.
  • Tekla Capital Management's biggest Q3 2019 reduction was Amgen, cutting an estimated $18.7M.
  • Tekla Capital Management fully exited Array Biopharma Inc in Q3 2019, selling an estimated $15M.
  • Tekla Capital Management's ten largest holdings make up 42% of its $2.29B portfolio in Q3 2019.
  • Tekla Capital Management opened 13 new positions and closed 18 in Q3 2019.
  • Tekla Capital Management's portfolio value fell 6.5% quarter-over-quarter to $2.29B.

Based on Tekla Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.